BACKGROUND AND OBJECTIVES: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated. Those analyzing liver and kidney volumes were blinded to treatment. RESULTS:Liver volumes significantly decreased from 1595 +/- 478 ml to 1524 +/- 453 ml with octreotide whereas they did not appreciably change with placebo. Changes in liver volumes were significantly different between the two treatment periods (-71 +/- 57 ml versus +14 +/- 85 ml). Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 +/- 431 ml to 1432 +/- 403 ml. Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes (r = 0.67) during octreotide but not during placebo treatment. Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 +/- 57 ml versus +71 +/- 107; placebo: +14 +/- 85 ml versus +162 +/- 114), but net reductions in liver (-85 +/- 103 ml) and kidney (-91 +/- 125 ml) volume growth on octreotide versus placebo were similar. CONCLUSIONS:Octreotide therapy reduces liver volumes in patients with ADPKD and is safe.
RCT Entities:
BACKGROUND AND OBJECTIVES: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated. Those analyzing liver and kidney volumes were blinded to treatment. RESULTS: Liver volumes significantly decreased from 1595 +/- 478 ml to 1524 +/- 453 ml with octreotide whereas they did not appreciably change with placebo. Changes in liver volumes were significantly different between the two treatment periods (-71 +/- 57 ml versus +14 +/- 85 ml). Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 +/- 431 ml to 1432 +/- 403 ml. Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes (r = 0.67) during octreotide but not during placebo treatment. Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 +/- 57 ml versus +71 +/- 107; placebo: +14 +/- 85 ml versus +162 +/- 114), but net reductions in liver (-85 +/- 103 ml) and kidney (-91 +/- 125 ml) volume growth on octreotide versus placebo were similar. CONCLUSIONS:Octreotide therapy reduces liver volumes in patients with ADPKD and is safe.
Authors: G Gyapay; J Morissette; A Vignal; C Dib; C Fizames; P Millasseau; S Marc; G Bernardi; M Lathrop; J Weissenbach Journal: Nat Genet Date: 1994-06 Impact factor: 38.330
Authors: Piero Ruggenenti; Andrea Remuzzi; Patrizia Ondei; Giorgio Fasolini; Luca Antiga; Bogdan Ene-Iordache; Giuseppe Remuzzi; Franklin H Epstein Journal: Kidney Int Date: 2005-07 Impact factor: 10.612
Authors: F Gaspari; N Perico; P Ruggenenti; L Mosconi; C S Amuchastegui; E Guerini; E Daina; G Remuzzi Journal: J Am Soc Nephrol Date: 1995-08 Impact factor: 10.121
Authors: Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth Journal: Gastroenterology Date: 2009-07-29 Impact factor: 22.682
Authors: Kyongtae T Bae; Fang Zhu; Arlene B Chapman; Vicente E Torres; Jared J Grantham; Lisa M Guay-Woodford; Deborah A Baumgarten; Bernard F King; Louis H Wetzel; Philip J Kenney; Marijn E Brummer; William M Bennett; Saulo Klahr; Catherine M Meyers; Xiaoling Zhang; Paul A Thompson; J Philip Miller Journal: Clin J Am Soc Nephrol Date: 2005-10-26 Impact factor: 8.237
Authors: Marie C Hogan; Tetyana V Masyuk; Linda Page; David R Holmes; Xujian Li; Eric J Bergstralh; Maria V Irazabal; Bohyun Kim; Bernard F King; James F Glockner; Nicholas F Larusso; Vicente E Torres Journal: Nephrol Dial Transplant Date: 2012-07-06 Impact factor: 5.992
Authors: Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales Journal: J Hepatol Date: 2015-06-01 Impact factor: 25.083
Authors: Maria J Perugorria; Tatyana V Masyuk; Jose J Marin; Marco Marzioni; Luis Bujanda; Nicholas F LaRusso; Jesus M Banales Journal: Nat Rev Gastroenterol Hepatol Date: 2014-09-30 Impact factor: 46.802